Sorrento Therapeutics, Inc. Receives Court Approval for $75 Million Financing in Chapter 11 CasePRNewsWire • 02/21/23
Sorrento Posts Form 8937 to Supplement its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)GlobeNewsWire • 02/19/23
Sorrento Issues Update to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common Stock (Nasdaq: SCLX, “Scilex”)GlobeNewsWire • 02/17/23
Sorrento Therapeutics, Inc. Receives Court Approval for "First Day" Employee Wages and Cash Management MotionsPRNewsWire • 02/16/23
Sorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 02/14/23
Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today's Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.GlobeNewsWire • 02/13/23
Sorrento Therapeutics stock plummets more than 60% on news of bankruptcy filingProactive Investors • 02/13/23
A biotech company that once claimed to have a 'cure' for COVID-19 just filed for bankruptcy, sending shares plunging 59%Business Insider • 02/13/23
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraineGlobeNewsWire • 02/12/23
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of StockholdersGlobeNewsWire • 02/05/23
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common StockGlobeNewsWire • 02/04/23
Sorrento Issues Supplement to its Previously Issued “FAQ” Regarding the Dividend of Scilex Holding Company Common StockGlobeNewsWire • 02/02/23